Glycemic Effects of Postmenopausal Hormone Therapy: The Heart and Estrogen/progestin Replacement Study: A Randomized, Double-Blind, Placebo-Controlled Trial

  1. Alka M. Kanaya, MD;
  2. David Herrington, MD, MHS;
  3. Eric Vittinghoff, PhD;
  4. Feng Lin, MS;
  5. Deborah Grady, MD, MPH;
  6. Vera Bittner, MD, MSPH;
  7. Jane A. Cauley, DrPH; and
  8. Elizabeth Barrett-Connor, MD
  1. From University of California, San Francisco, San Francisco, and University of California, San Diego, La Jolla, California; Wake Forest University School of Medicine, Winston-Salem, North Carolina; University of Alabama at Birmingham, Birmingham, Alabama; and University of Pittsburgh, Pittsburgh, Pennsylvania.
    1. Figure. Impaired fasting glucose was indicated by a serum glucose level of 6.0 to 6.9 µmol/L (110 to 125 mg/dL).
      View larger version:
      Figure. Impaired fasting glucose was indicated by a serum glucose level of 6.0 to 6.9 µmol/L (110 to 125 mg/dL). The flow diagram of the Heart and Estrogen/progestin Replacement Study.

    Summary for Patients

    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med January 7, 2003 vol. 138 no. 1 1-9
    1. AbstractFREE
    2. » Figures
    3. Full Text
    4. Full Text (PDF)
      1. Summary for Patients

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. November 17, 2009, 151 (10)
    1. Alert me to current issues